Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial compares imatinib with interferon and cytarabine for better outcomes in chronic myeloid leukemia, suggesting it is a more effective first-line treatment.
Key Points
- To evaluate the effectiveness of imatinib compared to interferon and low-dose cytarabine as first-line therapy for newly diagnosed chronic-phase chronic myeloid leukemia (CML).
- Compared imatinib against interferon alfa and low-dose cytarabine as initial treatment for CML
- Assessments included hematologic and cytogenetic responses
- Evaluated tolerability and progression rates to accelerated-phase or blast-crisis CML
- Imatinib demonstrated superior hematologic and cytogenetic responses compared to interferon plus cytarabine
- Lower likelihood of progression to accelerated-phase or blast-crisis CML was observed with imatinib
- Tolerability for imatinib was higher than that for the combination therapy
Cite This Study
O’Brien et al. (2003) studied this question.